Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Technology / AGAMREE Phase 1 Study Results
Tech clinical trial results

AGAMREE Phase 1 Study Results

Analysis based on 6 articles · First reported Jul 01, 2026 · Last updated Jul 01, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive Phase 1 clinical trial results for AGAMREE, conducted by Catalyst Pharmaceuticals and noted by Santhera Pharmaceuticals, suggest its potential for broader application in chronic inflammatory rare diseases. This could lead to increased sales and milestone payments for Santhera Pharmaceuticals and expanded market opportunities for Catalyst Pharmaceuticals, positively impacting their stock prices and the pharmaceutical industry focused on rare diseases.

pharmaceuticals biotechnology
Event Summary

Santhera Pharmaceuticals announced topline results from a Phase 1 clinical study of AGAMREE, conducted by its North American licensing partner, Catalyst Pharmaceuticals. The study, performed on healthy adult volunteers, indicated that AGAMREE exhibits glucocorticoid and anti-inflammatory activity without significant immunosuppressive effects. This supports the drug's potential for treating a wide range of chronic inflammatory rare diseases, beyond its current approval for Duchenne muscular dystrophy. The findings showed comparable cortisol suppression to deflazacort but with less pronounced immunosuppressive biomarker effects at clinical doses. Clinically relevant immunosuppressive effects were only observed at the highest dose, above currently approved AGAMREE dosing. Santhera Pharmaceuticals is eligible for sales-based milestone payments and royalties from Catalyst Pharmaceuticals under their exclusive license agreement.

Key Actions
90 Catalyst Pharmaceuticals conducted clinical study
85 Santhera Pharmaceuticals noted results
Entities Involved
stock
Santhera Pharmaceuticals
Santhera Pharmaceuticals is the developer of AGAMREE and benefits from positive clinical trial results, which could lead to expanded indications and increased sales-based milestone payments and royalties from its licensing partners.
Importance 90.0 Sentiment 70.0
stock
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals conducted the Phase 1 study of AGAMREE and holds commercialization rights in North America. Positive results support its potential to expand the drug's use beyond Duchenne muscular dystrophy, increasing its market potential.
Importance 80.0 Sentiment 60.0
oth
Duchenne muscular dystrophy
Duchenne muscular dystrophy is the initial approved indication for AGAMREE. The study's findings reinforce AGAMREE's efficacy and safety profile in this context while also suggesting potential for new indications.
Importance 50.0 Sentiment 0.0
priv
ReveraGen
ReveraGen is the original licensor of AGAMREE to Santhera Pharmaceuticals. While not directly involved in this study, the positive results indirectly benefit ReveraGen through its licensing agreement with Santhera Pharmaceuticals.
Importance 20.0 Sentiment 0.0
priv
Sperogenix Therapeutics
Sperogenix Therapeutics holds commercialization rights for AGAMREE in China and parts of Southeast Asia. Positive clinical data could support future market expansion in its licensed territories.
Importance 10.0 Sentiment 0.0
stock
Nxera Pharma
Nxera Pharma holds commercialization rights for AGAMREE in Japan, South Korea, Australia, and New Zealand. Positive clinical data could support future market expansion in its licensed territories.
Importance 10.0 Sentiment 0.0
govactor
Hong Kong — Department of Health (Hong Kong)
The Hong Kong — Department of Health (Hong Kong) is mentioned as having approved AGAMREE for Duchenne muscular dystrophy in Hong Kong, indicating the drug's established regulatory status.
Importance 10.0 Sentiment 0.0
govactor
Canada — Health Canada
Canada — Health Canada is mentioned as having approved AGAMREE for Duchenne muscular dystrophy in Canada, indicating the drug's established regulatory status.
Importance 10.0 Sentiment 0.0
govactor
China — National Medical Products Administration
The China — National Medical Products Administration is mentioned as having approved AGAMREE for Duchenne muscular dystrophy in China, indicating the drug's established regulatory status.
Importance 10.0 Sentiment 0.0
govactor
United Kingdom — Medicines and Healthcare products Regulatory Agency
The United Kingdom — Medicines and Healthcare products Regulatory Agency is mentioned as having approved AGAMREE for Duchenne muscular dystrophy in the UK, indicating the drug's established regulatory status.
Importance 10.0 Sentiment 0.0
govactor
Switzerland — Swissmedic
Switzerland — Swissmedic is mentioned as having approved AGAMREE for Duchenne muscular dystrophy in Switzerland, indicating the drug's established regulatory status.
Importance 10.0 Sentiment 0.0
govactor
International — European Commission
The International — European Commission is mentioned as having approved AGAMREE for Duchenne muscular dystrophy in the EU, indicating the drug's established regulatory status.
Importance 10.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration is mentioned as having approved AGAMREE for Duchenne muscular dystrophy in the U.S., indicating the drug's established regulatory status.
Importance 10.0 Sentiment 0.0
Relationships
Santhera Pharmaceuticals licensor, investee ↔ Nxera Pharma Santhera Pharmaceuticals is the licensor of AGAMREE to Nxera Pharma, granting exclusive commercialization rights in Japa
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.